North America Antibody Drug Conjugate Market Size and Trends for 2026

The North America antibody drug conjugate (ADC) market size is projected to grow from USD 7.16 billion in 2025 to USD 16.80 billion by 2035, at a compound annual growth rate (CAGR) of 8.90% from 2026 to 2035.

Key Takeaways

• Global antibody drug conjugate (ADC) industry poised to reach USD 14.76 billion by 2026.
• North America dominated the antibody drug conjugate market with the largest revenue share of 53% in 2025.
• By application, the breast cancer segment has generated the biggest revenue share of 49% in 2025.
• By application, the blood cancer segment is expected to grow at the fastest rate during the forecast period.
• By product, the kadcyla segment held the largest share of the market in 2025.
• By product, the enhertu segment is estimated to grow at the fastest CAGR during 2025-2035.
• By target, the HER2 or human epidermal growth factor receptor 2 target type segment held the largest market share in 2025.
• By target, the CD22 segment is anticipated to grow at the fastest rate during the forecast period.
• By technology, the cleavable linker segment has held a major revenue share of 73% in 2025.

Antibody Drug Conjugate Market

Typically, an antibody-drug conjugate (ADC) is made up of a cytotoxic drug and a monoclonal antibody (mAb) that have been covalently linked by a chemical linker. The market for antibody drug conjugates is expanding as a result of its ability to combine the benefits of highly potent killing and highly specific targeting to accurately and effectively eradicate cancer cells. The antibody drug conjugate market has emerged as a center for anticancer drug research and development.

AI in Driving Growth in Antibody Drug Conjugate Market

Artificial Intelligence (AI) is set to revolutionize the Antibody Drug Conjugate (ADC) market by enhancing efficiency, precision, and innovation. AI algorithms can expedite the drug discovery process by analyzing vast datasets to identify potential antibody-drug combinations that are most likely to succeed. This reduces the time and cost associated with traditional trial-and-error methods. Additionally, AI can optimize the design of ADCs by predicting how different molecular structures will interact with target cells, thus improving efficacy and minimizing side effects.

In clinical trials, AI-driven analytics can predict patient responses, allowing for more personalized treatment plans and improving overall outcomes. AI can also streamline manufacturing processes by monitoring production in real-time, identifying potential issues before they become significant problems, and ensuring consistent quality.

AI's capability to process and analyze large volumes of biomedical literature and patient data can uncover new insights and trends that inform future research and development. By integrating AI into the ADC market, companies can accelerate innovation, reduce costs, and improve patient outcomes, ultimately driving market growth and enhancing the therapeutic potential of antibody-drug conjugates.

Top Companies in the Antibody Drug Conjugate Market

• ADC Therapeutics SA
• AbbVie
• Astellas Pharma, Inc.
• GlaxoSmithKline Plc
• Daiichi Sankyo Company Ltd.
• Gilead Sciences, Inc.
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
• Takeda Pharmaceutical Company Ltd.
• Seagen, Inc.

Segments Covered in the Report

By Application

• Blood Cancer
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Other Cancer

By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

By Target

• HER2
• CD22
• CD30
• Others

By Technology

• Type
  • Cleavable Linker
  • Non-cleavable Linker
  • Linkerless
• Linker Technology Type
  
  • VC
  • Sulfo-SPDB
  • VA
  • Hydrazone
  • Others
• Payload Technology
  
  • MMAE
  • MMAF
  • DM4
  • Camptothecin
  • Others